Zacks Research upgraded shares of Huize (NASDAQ:HUIZ – Free Report) to a hold rating in a report issued on Tuesday,Zacks reports.
Separately, Weiss Ratings upgraded shares of Huize from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, September 28th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce”.
Read Our Latest Research Report on HUIZ
Huize Stock Down 7.1%
Shares of HUIZ opened at $2.35 on Tuesday. Huize has a 52-week low of $1.04 and a 52-week high of $4.05. The firm’s fifty day moving average is $1.50 and its two-hundred day moving average is $1.44. The stock has a market cap of $23.71 million, a PE ratio of 78.33 and a beta of 0.97.
Huize (NASDAQ:HUIZ – Get Free Report) last issued its earnings results on Saturday, August 15th. The company reported $0.14 EPS for the quarter. The business had revenue of $52.98 million during the quarter.
About Huize
Huize Limited is a China-based insurance technology company that operates an online insurance product and service platform. Through its digital channels, the company helps consumers research, compare and purchase insurance products, while providing ongoing policy-management and customer-support services.
Huize primarily focuses on protection and long-term insurance products, including life, health, critical illness, medical and accident coverage. The company also works with insurance carriers by providing digital distribution, customer acquisition and technology-enabled services designed to support the marketing and sale of insurance products.
Founded in 2006 and headquartered in Shenzhen, China, Huize serves consumers and insurance partners in the Chinese market.
See Also
- Five stocks we like better than Huize
- Are RTX Corporation and Northrop Grumman Ready to Break Out?
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
Receive News & Ratings for Huize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Huize and related companies with MarketBeat.com's FREE daily email newsletter.
